Apixaban

Apixaban ( CAS: 503612-47-3 )

Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and the prevention of stroke in atrial fibrillation. It is a direct factor Xa inhibitor. Apixaban has been available in Europe since May 2011. The drug was developed in a joint venture by Pfizer and Bristol-Myers Squibb.

Overdose of apixaban may result in a higher risk of bleeding. In the event of haemorrhagic complications, treatment must be discontinued. There is no established way to reverse the anticoagulant effect of apixaban, which can be expected to persist for about 24 hours after the last dose (i.e., about two half-lives). A specific antidote is not available. Although treatment with apixaban does not require routine monitoring of exposure, the Rotachrom® anti-FXa assay may be useful in exceptional situations where knowledge of apixaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery.

Discontinuation

There is increased risk of (mainly ischemic) stroke with discontinuation of apixaban. Discontinuing apixaban in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from apixaban to warfarin in clinical trials in patients with nonvalvular atrial fibrillation within the first 30 days of transition. This resumption of events was probably related to inadequate control of anticoagulation, but induction of a hypercoagulable state by long-term treatment with the NOAC has not been ruled out. If apixaban must be discontinued for a reason other than pathological bleeding, consider coverage with another anticoagulant.